Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.40 |
| ▸ | DRD3 | P35462 | 5/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL27669021 | 0.98 | DRD2 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| Biphenyl SCHEMBL4360975 | 0.93 | ADORA2A (0.38) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL1712875 | 0.87 | DRD2 (0.43) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL776975 | 0.85 | SLC6A2 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL30919460 | 0.85 | SLC6A2 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL7023211 | 0.82 | DRD2 (0.42) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL779828 | 0.81 | EPAS1 (0.50) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL31305332 | 0.81 | EPAS1 (0.50) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL25323447 | 0.80 | FABP1 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL13580797 | 0.80 | DRD2 (0.36) | DRD2DRD3DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440581-B2 | Fluorophores for super-resolution imaging | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-10-14 | — | — | US | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| CN-113692401-A | Process for producing aromatic amino acid derivative | 中外制药株式会社 | 2021-11-23 | — | — | CN | disclosed |
| CN-113614085-A | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20210085805-A1 | FLUOROPHORES FOR SUPER-RESOLUTION IMAGING | HOWARD HUGHES MEDICAL INSTITUTE | 2021-03-25 | — | — | US | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10333172-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| WO-2014196930-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-12-11 | — | — | WO | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| WO-2011121350-A1 | 4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | WO | disclosed |
| CN-1854133-B | Heterocycle-bearing onium salts | WAKO PURE CHEM IND LTD | 2010-11-10 | — | — | CN | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-100475803-C | Heterocyclic onium salt | WAKO PURE CHEM IND LTD (JP) | 2009-04-08 | — | — | CN | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| CN-1854133-A | Heterocycle-bearing onium salts | WAKO PURE CHEM IND LTD (JP) | 2006-11-01 | — | — | CN | disclosed |
| CN-1622943-A | Heterocyclic onium salt | WAKO PURE CHEM IND LTD (JP) | 2005-06-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085805-A1 | FLUOROPHORES FOR SUPER-RESOLUTION IMAGING | CHAT, FABP7, CD68 | DRD2 751/4885DRD3 1278/4885DRD4 952/4885 |
| US-12440581-B2 | Fluorophores for super-resolution imaging | CHAT, FABP7, CD68 | DRD2 751/4885DRD3 1278/4885DRD4 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.